Guías Simplificadas para el Manejo de: Enfermedad Pulmonar Obstructiva Crónica, Neumonía y Asma Bronquial

Objectives

This national guideline establishes a comprehensive preventive, diagnostic and therapeutic framework for chronic obstructive pulmonary disease, community-acquired pneumonia and bronchial asthma in Nicaragua. It aims to equip health personnel to deliver comprehensive care, improve affected people’s quality of life, strengthen health-service networks at every level of care and contribute to safeguarding the right to health.[1][2][3]

• Standardise classification and management of chronic obstructive pulmonary disease using symptoms, exposure history and post-bronchodilator spirometry where available, including forced expiratory volume in one second and the forced expiratory volume in one second to forced vital capacity ratio.[3][4]
• Reduce chronic obstructive pulmonary disease risk by promoting smoking cessation, reducing exposure to wood smoke, occupational smoke and harmful gases, and supporting influenza and pneumococcal immunisation, respiratory rehabilitation and patient education.[3][4]
• Improve identification and management of community-acquired pneumonia through clinical and radiological assessment, pathogen and risk-factor assessment, severity classification, empirical treatment and referral of severe or complicated cases.[5][6]
• Strengthen asthma diagnosis, classification and control by recognising chronic inflammatory airway disease with variable reversible obstruction and using clinical history, spirometry with bronchodilator testing and measures of symptom control.[7][8]
• Support sustained asthma self-management through continuous, regularly evaluated and socioculturally adapted education for patients and families.[9]
• Target adults affected by the three respiratory conditions and the health personnel responsible for their care in Nicaragua.[3]

Implementation

Implementation combines Ministry of Health stewardship, national dissemination and follow-up through health-service networks with condition-specific clinical pathways for prevention, diagnosis, treatment, education and specialist referral. The guidance applies across public and private establishments that diagnose and treat these respiratory conditions, although public-sector implementation and follow-up are specifically assigned to the General Directorate for Extension of Care Quality.[1][2]

• Coordinate implementation through the Ministry of Health, which is responsible for preparing, approving, applying, supervising and evaluating technical standards, policies, plans, programmes, projects, manuals and instructions, and for regulating and monitoring health actions across the sector.[1]
• Disseminate the ministerial agreement and guideline through the General Directorate of Health Regulation to directors of Local Comprehensive Health-Care Systems and to public and private health establishments.[2]
• Apply the guidance through the national health-service network and its different levels of care, using health personnel as the principal delivery workforce for comprehensive respiratory care.[1]
• Manage chronic obstructive pulmonary disease through severity-based treatment, beginning with short-acting bronchodilators and escalating, where indicated, to combined bronchodilators, inhaled beclometasone and consideration of prolonged-release theophylline in very severe disease.[4]
• Address chronic obstructive pulmonary disease exacerbations by increasing bronchodilator treatment and using antibiotics or short courses of systemic corticosteroids where clinically indicated, while referring patients when diagnosis or severity is uncertain, treatment fails, exacerbations are frequent or comorbidity is significant.[4]
• Educate people with chronic obstructive pulmonary disease to avoid tobacco and other toxic habits, avoid self-medication, undertake appropriate physical exercise and respiratory therapy, attend regular reviews and adapt work to physical capacity where necessary.[4]
• Diagnose community-acquired pneumonia through clinical and radiological examination, treating diagnosis as presumptive when radiography is unavailable, and principally reserving Gram stain, sputum culture and blood culture for hospitalised patients or suspected unusual pathogens.[5]
• Stratify pneumonia treatment between lower-risk ambulatory patients, ambulatory patients with risk factors and hospitalised patients, then adjust antimicrobial management according to clinical response and consider alternative diagnoses or regimens when response is inadequate.[6]
• Refer pneumonia cases with severe disease, poor response or complications, including pleural effusion, empyema, lung abscess, meningitis or endocarditis, for specialist care.[6][7]
• Assess asthma-associated exposures and symptom patterns, including allergy, viral infection, occupational exposure, aspirin or beta-blockers, nocturnal symptoms and exercise-related symptoms.[7]
• Use a five-step asthma treatment framework, escalating treatment where asthma remains uncontrolled despite correct use and considering step-down only after control has been maintained for several months.[10]
• Provide asthma education on controller and reliever medicines, correct inhaler technique, trigger avoidance, peak expiratory flow monitoring, recognition of deterioration and appropriate responses to loss of control.[9]
• Refer asthma patients for specialist review when asthma remains uncontrolled, following a severe crisis including intensive-care admission, or when asthma occurs during pregnancy.[9]
• Assess treatment response and control using clinical measures, including symptoms, reliever use, activity limitation, nocturnal symptoms, exacerbations, forced expiratory volume in one second or peak expiratory flow, and validated asthma questionnaires.[8][11]

Monitoring & Evaluation

Monitoring and accountability combine Ministry of Health oversight of health standards with condition-specific clinical assessment and follow-up. The guideline assigns implementation follow-up in public facilities to the General Directorate for Extension of Care Quality, but does not establish a unified national reporting, surveillance, indicator or accountability framework.[12][1][2]

• Supervise, control and evaluate compliance with the General Health Law, its regulations, health policies and technical standards through the Ministry of Health’s stewardship functions.[12][1]
• Implement and follow up the guidance in public health establishments through the General Directorate for Extension of Care Quality.[2]
• Assess chronic obstructive pulmonary disease severity using post-bronchodilator forced expiratory volume in one second (FEV1) and an FEV1/forced vital capacity ratio below 0.7.[4]
• Evaluate pneumonia through clinical findings, radiological evidence where available, severity criteria and response to antimicrobial treatment.[5][6]
• Reassess pneumonia when there is no clinical response within 48 to 72 hours, or earlier deterioration, including review of the antimicrobial regimen, factors affecting effectiveness and alternative diagnoses such as pulmonary tuberculosis.[6]
• Use pneumonia response timeframes as clinical follow-up measures: fever resolution within 2 to 4 days, leucocytosis resolution within 4 to 5 days, physical examination abnormalities that may persist for up to 7 days, and radiological abnormalities that may persist for up to 4 weeks.[6]
• Assess asthma severity and control through daytime and nocturnal symptoms, activity limitation, reliever use, exacerbation frequency, lung function measured by FEV1 or peak expiratory flow, and validated instruments including the Asthma Control Test and Asthma Control Questionnaire.[8][11]
• Adjust asthma treatment according to control status, classifying asthma as poorly controlled when more than three partially controlled characteristics are present.[11]
• Monitor asthma symptoms and peak expiratory flow, recognise loss of control, and evaluate patient and family education regularly.[9]
• Recognise that the supplied sections do not specify operational performance targets, routine reporting schedules, data flows, surveillance arrangements, audit methods, public reporting requirements or sanctions for non-compliance.[2][5][8][9]

Costing & Financing

Financing and insurance fall within the Ministry of Health’s wider policy and planning responsibilities, but the guideline excerpts provide no dedicated financial plan. No budget, implementation cost, funding source, allocation formula, resource-mobilisation mechanism, funding-gap estimate or economic assumption is specified.[1][2][6][11]

• Identify health financing and insurance as policy and planning areas under Ministry of Health responsibility.[1]
• Require clinical resources implied by the guidance, including spirometry where available, radiography for diagnostic certainty in pneumonia, medicines, immunisation, respiratory rehabilitation, patient education and specialist referral; the excerpts do not quantify their costs or funding sources.[3][4][5][10][9]
• Provide no explicit budget allocation, unit cost, procurement arrangement, donor contribution, domestic financing commitment, affordability assessment or funding-gap analysis for chronic obstructive pulmonary disease, pneumonia or asthma services.[2][7][11][10]